Breumwinkler0745

ighly accurate geometry and linear attenuation coefficient vs. those of the LLNL phantom. The difference in CT number was ± 2% HU for the LLNL phantom and ± 4% HU for the human CT image based on a CT examination conducted using the chest CT protocol. Moreover, both lungs weighed 734 g to 1,246 g, within the range of the reference value of the ICRU report. These results demonstrate that a new lung model based on average linear dimension measurement in a group with average physique simulated the features and physical properties of real human lungs and facilitated further studies for phantom construction.

No Abstract.

No Abstract.

To determine the sources of variability for cochlear duct length (CDL) measurements for the purposes of fine-tuning cochlear implants (CI) and to propose a set of standardized landmarks for computed tomography (CT) pitch mapping.

This was a retrospective cohort study involving 21 CI users at a tertiary referral center. The intervention involved flat-panel CT image acquisition and secondary reconstructions of CIs in vivo. The main outcome measures were CDL measurements, CI electrode localization measurements, and frequency calculations.

Direct CT-based measurements of CI and intracochlear landmarks are methodologically valid, with a percentage of error of 1.0% ± 0.9%. Round window (RW) position markers (anterior edge, center, or posterior edge) and bony canal wall localization markers (medial edge, duct center, or lateral edge) significantly impact CDL calculations [F(2, 78) = 9.9, p < 0.001 and F(2, 78) = 1806, p < 0.001, respectively]. These pitch distortions could be as large as 11 semitones. Whssociated pitch outcomes.

The objectives of the study were to (1) evaluate the impact of hearing loss on children's ability to benefit from F0 differences between target/masker speech in the context of aided speech-in-speech recognition and (2) to determine whether compromised F0 discrimination associated with hearing loss predicts F0 benefit in individual children. Pifithrin-μ order We hypothesized that children wearing appropriately fitted amplification would benefit from F0 differences, but they would not show the same magnitude of benefit as children with normal hearing. Reduced audibility and poor suprathreshold encoding that degrades frequency discrimination were expected to impair children's ability to segregate talkers based on F0.

Listeners were 9 to 17 year olds with bilateral, symmetrical, sensorineural hearing loss ranging in degree from mild to severe. A four-alternative, forced-choice procedure was used to estimate thresholds for disyllabic word recognition in a 60-dB-SPL two-talker masker. The same male talker produced target and masripheral encoding that are not characterized in standard clinical assessments.

Currently, bilateral cochlear implants (CIs) are independently programmed in clinics using frequency allocations based on the relative location of a given electrode from the end of each electrode array. By pairing electrodes based on this method, bilateral CI recipients may have decreased sensitivity to interaural time differences (ITD) and/or interaural level differences (ILD), two cues critical for binaural tasks. There are multiple different binaural measures that can potentially be used to determine the optimal way to pair electrodes across the ears. Previous studies suggest that the optimal electrode pairing between the left and right ears may vary depending on the binaural task used. These studies, however, have only used one reference location or a single bilateral CI user. In both instances, it is difficult to determine if the results that were obtained reflect a measurement error or a systematic difference across binaural tasks. It is also difficult to determine from these studies if the difference cue measured, but only at the basal end of the array.

The results suggest that optimal electrode pairings differ depending on the cue measured to determine optimal pairing, at least for the basal end of the array. This also suggests that the improvements seen when using optimally paired electrodes may be tied to the particular percept being measured both to determine electrode pairing and to assess performance, at least for the basal end of the array.

The results suggest that optimal electrode pairings differ depending on the cue measured to determine optimal pairing, at least for the basal end of the array. This also suggests that the improvements seen when using optimally paired electrodes may be tied to the particular percept being measured both to determine electrode pairing and to assess performance, at least for the basal end of the array.

Polygenic scores (PGS) are used to quantify the genetic predisposition for heritable traits, with hypothesized utility for personalized risk assessments. Lipid PGS are primed for clinical translation, but evidence-based practice changes will require rigorous PGS standards to ensure reproducibility and generalizability. Here we review applicable reporting and technical standards for dyslipidemia PGS translation along phases of the ACCE (Analytical validity, Clinical validity, Clinical utility, Ethical considerations) framework for evaluating genetic tests.

New guidance suggests existing standards for study designs incorporating the ACCE framework are applicable to PGS and should be adopted. One recent example is the Clinical Genomics Resource (ClinGen) and Polygenic Score Catalog's PRS reporting standards, which define minimal requirements for describing rationale for score development, study population definitions and data parameters, risk model development and application, risk model evaluation, and translational considerations, such as generalizability beyond the target population studied.

Lipid PGS are likely to be integrated into clinical practice in the future. Clinicians will need to be prepared to determine if and when lipid PGS is useful and valid. This decision-making will depend on the quality of evidence for the clinical use of PGS. Establishing reporting standards for PGS will help facilitate data sharing and transparency for critical evaluation, ultimately benefiting the efficiency of evidence-based practice.

Lipid PGS are likely to be integrated into clinical practice in the future. Clinicians will need to be prepared to determine if and when lipid PGS is useful and valid. This decision-making will depend on the quality of evidence for the clinical use of PGS. Establishing reporting standards for PGS will help facilitate data sharing and transparency for critical evaluation, ultimately benefiting the efficiency of evidence-based practice.